Association of hepcidin and anemia in early chronic kidney disease

Sonkar, Satyendra Kumar; Singh, Neeraj; Sonkar, Gyanendra Kumar; Pandey, Sushma; Bhosale, Vivek; Usman, Kauser

doi:10.4103/1319-2442.256838

Cited by 15 publications

(21 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because hepcidin was measured via enzyme-linked immunosorbent assay, the discrepancy between the results may be due to the assay or a different patient population. 48…”

Section: Hepcidinmentioning

confidence: 99%

Iron metabolism and management: focus on chronic kidney disease

Agarwal

2021

Kidney International Supplements

View full text Add to dashboard Cite

Anemia is common in patients with chronic kidney disease (CKD) and results from the dysregulation of iron metabolism and erythropoiesis. Hepcidin is a key regulator of iron availability and leads to iron sequestration during the state of iron repletion. Decreases in the level of hepcidin in the presence of hypoxia and/or iron limitation allow for greater iron availability for erythropoiesis. However, kidney excretion of hepcidin decreases as the severity of CKD increases, whereas production of hepcidin is increased under inflammatory conditions often present in patients with CKD, both of which contribute to anemia. Assessment of iron status is, therefore, essential in the treatment of anemia. However, current laboratory tests for the determination of the adequate supply of iron have many limitations, including diurnal variation in the levels of biomarkers, lack of standardized reference methods across laboratories, and confounding by the presence of inflammation. In addition, the current treatment paradigm for anemia of CKD can further disrupt iron homeostasis; for example, treatment with erythropoiesis-stimulating agents in the absence of supplemental iron can induce functional iron deficiency. Moreover, supplemental iron can further increase levels of hepcidin. Several novel therapies, including hypoxia-inducible factor prolyl hydroxylase inhibitors and hepcidin inhibitors/antagonists, have shown promise in attenuating the levels and/or activity of hepcidin in anemia of CKD, thus ensuring the availability of iron for erythropoiesis.

show abstract

“…Because hepcidin was measured via enzyme-linked immunosorbent assay, the discrepancy between the results may be due to the assay or a different patient population. 48…”

Section: Hepcidinmentioning

confidence: 99%

Iron metabolism and management: focus on chronic kidney disease

Agarwal

2021

Kidney International Supplements

View full text Add to dashboard Cite

show abstract

“…In previous studies, branched chain amino acids (BCAA), especially valine and leucine decreased in plasma of CKD patients, but the levels of isoleucine seem to be unchanged. 42 Although in another study, valine, isoleucine, and leucine were lower in the patients with end-stage renal disease (ESRD) than in control group. 43 The level of plasma amino acids may be affected by different disease stages, individual differences, and different detection methods adopted by different research institutions.…”

Section: Discussionmentioning

confidence: 91%

Dynamic cellular changes in acute kidney injury caused by different ischemia time

Shan¹,

Wang²,

Chang³

et al. 2023

iScience

View full text Add to dashboard Cite

“…Serum vitamin D concentration and Hb concentration in patients with end-stage renal disease, and vitamin D was shown to be an independent risk factor for anaemia in such patients. In addition, Sonkar et al (2019) showed that patients with CKD and low Hb concentrations had higher circulating PTH concentrations, and noted a positive correlation between their vitamin D and Hb concentrations. These results suggest that a lack of vitamin D and secondary hyperparathyroidism may be closely associated with renal anaemia.…”

Section: Discussionmentioning

confidence: 96%

Vitamin D deficiency as risk factor associated with anemia and outcome hemodialysis patients

Ulrahman

Sharba

2022

ijhs

View full text Add to dashboard Cite

Background: Vitamin D deficiency and anemia are common problems that increased pathophysiology in the chronic kidney disease (CKD) undergoing hemodialysis (HD). This study was conducted to assess the association between vitamin D and anemia status in HD patients. Methods: This was a cross-sectional study of 65 HD patients and EPO therapy were enrolled; compared with 25 age matched healthy individuals as controls. The current study was investigated serum hepcidin, iron status was included serum ferritin and iron levels, anemia hematological indices such as RBC, Hb, MCV, and MCH, in addition to other clinical parameters of kidney function, and C-reactive protein (CRP) as inflammation markers were performed in both HD patients and controls. Results: The mean patient age was (45.65±13.34) years, with dialysis vintage of median (IQR) was (12 (3-36) month. serum hepcidin were highly significantly increase in HD patients than in the control group (622.3±139.6, and 465.16±80.31pg/ml, respectively p = 0.0001). serum hepcidin significantly associated with 37% anemia severity about (692.4±119.8) pg/ml more than patient with 49.2% of moderate about (605.3±117.7) pg/ml, (p=0.007) as compared with 13.8% of mild anemia groups (531.8±99.12) pg/ml, (p=0.001).

show abstract

Association of hepcidin and anemia in early chronic kidney disease

Cited by 15 publications

References 1 publication

Iron metabolism and management: focus on chronic kidney disease

Iron metabolism and management: focus on chronic kidney disease

Dynamic cellular changes in acute kidney injury caused by different ischemia time

Vitamin D deficiency as risk factor associated with anemia and outcome hemodialysis patients

Contact Info

Product

Resources

About